Vascular dementia and Alzheimer's are the two most common forms of dementia, but they start differently, progress differently, and are treated differently. Alzheimer's usually begins with memory loss and declines slowly, while vascular dementia—cognitive decline caused by reduced blood flow to the brain—often begins with problems in judgment and planning and can worsen in sudden steps after strokes.
The practical difference matters most at treatment. According to the NIA's vascular dementia overview, Alzheimer's is the leading cause of dementia and vascular dementia is the second. Yet only Alzheimer's now has drugs that target its underlying disease process; vascular dementia care focuses on protecting the blood vessels that feed the brain.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What each condition actually is
- How the symptoms differ
- How the two progress over time
- How treatment differs
- What a reader can do now
- Frequently Asked Questions
What each condition actually is
Alzheimer's disease is driven by abnormal protein buildup—especially beta-amyloid—that damages and kills brain cells over time. It is the most common cause of dementia, and its hallmark first symptom is trouble forming new memories. Vascular dementia comes from interrupted or reduced blood flow to brain tissue, caused by strokes or small-vessel disease that quietly narrows tiny blood vessels.
When brain cells lose their oxygen and nutrient supply, they are injured or die. These two often travel together. Per StatPearls at the NIH, vascular dementia accounts for roughly 15–20% of dementia cases in North America and Europe, but "pure" vascular dementia is less common because many people have mixed Alzheimer's-plus-vascular changes at the same time.
How the symptoms differ
The first symptoms often point to the diagnosis. Alzheimer's typically opens with memory loss—forgetting recent conversations, repeating questions, misplacing items in odd places. Vascular dementia tends to hit thinking skills before memory.
The NIA notes it often begins with impaired judgment, trouble planning or organizing, and slowed thinking, along with early problems in gait and coordination. A person may struggle to follow a multi-step task or manage finances while still recalling recent events fairly well. These are patterns, not rules. Overlap is common, and only a clinician can sort out the cause after an exam and imaging.
- Alzheimer's first: short-term memory loss, word-finding trouble, disorientation
- Vascular dementia first: poor judgment, difficulty planning, unsteady walking, slowed processing
How the two progress over time
Progression is one of the clearest dividing lines. Alzheimer's usually declines gradually and steadily over a span of years, with each stage blending into the next. Vascular dementia can follow a "step-wise" course.
As the Alzheimer's Association explains, symptoms may stay stable for a while, then drop suddenly after a new stroke, then plateau again. That said, vascular dementia caused by small-vessel disease can also decline steadily and look much like Alzheimer's. A sudden, noticeable worsening of thinking or function is a warning sign worth urgent medical attention. It may signal a new stroke, which is both a cause of further decline and a treatable emergency.
How treatment differs
This is where the two paths separate most sharply. The FDA has approved no drug specifically to treat vascular dementia. Instead, care centers on controlling the vascular risk factors—high blood pressure, diabetes, high cholesterol, and smoking—that drive further brain damage. Alzheimer's now has disease-targeting options.
The FDA fully approved two anti-amyloid antibodies for early Alzheimer's: lecanemab (Leqembi) in July 2023 and donanemab (Kisunla) in July 2024, for mild cognitive impairment or mild dementia with confirmed amyloid. These drugs slow decline—they do not stop or reverse it—and carry a risk of brain swelling or bleeding (ARIA) that requires MRI monitoring. Two cautions matter here. These amyloid drugs are indicated only for Alzheimer's with confirmed beta-amyloid, not for vascular dementia. And older symptomatic Alzheimer's drugs—cholinesterase inhibitors like donepezil, plus memantine—show only modest, off-label benefit in vascular dementia and are not FDA-approved for it, according to Cleveland Clinic.
What a reader can do now
Because vascular dementia is driven by cardiovascular and stroke risk, prevention is the strongest evidence-based tool you have. The NIA frames aggressive vascular risk-factor management as the primary strategy—unlike Alzheimer's, where amyloid-targeting therapy is now available.
- Get an accurate diagnosis: ask for cognitive testing and brain imaging to identify the cause
- Control blood pressure, blood sugar, and cholesterol with your doctor
- Stop smoking and treat conditions that raise stroke risk, such as atrial fibrillation
- If early Alzheimer's is suspected, ask whether amyloid testing and antibody treatment fit your case
- Treat any sudden decline as possible stroke and seek emergency care
Frequently Asked Questions
Can someone have both vascular dementia and Alzheimer's?
Yes. Mixed pathology is common, which is why "pure" vascular dementia is relatively rare and diagnosis can be complex.
Do the new Alzheimer's drugs help vascular dementia?
No. Lecanemab and donanemab are indicated only for Alzheimer's with confirmed beta-amyloid, not for vascular dementia.
Why does controlling blood pressure matter so much in vascular dementia?
Because the damage comes from strokes and small-vessel disease, managing blood pressure and related risks is the main way to slow further brain injury.
